Asundexian (also known as BAY2433334) will be given a speedy review by the US regulator as a secondary preventative treatment for people with ischaemic stroke, specifically those with non- cardioembolic risk factors like narrowed arteries.
The decision gives Bayer a shot at narrowing the gap with its main rivals in the category – Bristol-Myers Squibb and Johnson & Johnson – which are thought to be out in front the in race to bring an oral FXIa inhibitor to market with their milvexian candidate.
